Helen Jenkins

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

Éric Lefebvre, Graeme Moyle, Ran Reshef et al. · PLoS ONE · 2016 · 312 citations · Full text

Medicine, Immunology, Pharmacology +17

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of <scp>TAK</scp>‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

Helen Jenkins, Yuichi Sakurai, Akira Nishimura et al. · Alimentary Pharmacology & Therapeutics · 2015 · 307 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

Yuuichi Sakurai, Akira Nishimura, Gale Kennedy et al. · Clinical and Translational Gastroenterology · 2015 · 190 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

SGS742: the first GABAB receptor antagonist in clinical trials

Wolfgang Froestl, Michela Gallagher, Helen Jenkins et al. · Biochemical Pharmacology · 2004 · 189 citations

Medicine, Pharmacology, Pharmacotherapy +12

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

Joanne M. Munck, Michael A. Batey, Yan Zhao et al. · Molecular Cancer Therapeutics · 2012 · 131 citations · Full text

Medicine, Oncology, Pharmacology +11